Pioneering biotechnology company Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has developed a breakthrough lipid-based system that facilitates more efficient delivery of bioactive compounds—not only enhancing bio-absorption and bioavailability but also improving taste, smell and the onset of action.
Supreme Pharmaceuticals Inc. (TSXV: FIRE) announces that 7ACRES' first month of sales exceeded $1,500,000, and that such sales will be recorded in the quarter ended September 30, 2017.
Algae Dynamics Corp. (OTCQB: ADYNF), a company engaged in developing unique health products and pharmaceuticals that utilize hemp, cannabis and algae oils, is making international news through its current collaboration with the University of Western Ontario (now rebranded as Western University).
InMed Pharmaceuticals, Inc. (CSE: IN; OTCQB: IMLFF), has seen a strong upward trend over the past few weeks, going from a close of $.27 at the end of August to $.50 currently on the back of strong announcements, and people are taking notice.
PotNetwork Holding, Inc. (OTC: POTN) this morning announced that its Diamond CBD subsidiary has been selected as an exclusive premier sponsor of Tommy Chong’s Blazer’s Cup, a large cannabis festival set to take place beginning on December 2, 2017, in San Bernardino, California.
ChineseInvestors.com, Inc. (OTCQB: CIIX) announced in an 8K SEC filing that Paul Dickman has returned as its chief financial officer, effective September 25, 2017.
The cannabidiol market is large and diverse; just a few years ago, it was rather small but by 2015, consumer sales had reached $202 million, according to the CBD Report published by The Hemp Business Journal. Cannabidiol sales are expected to grow to over $2 billion by 2020.
Vancouver, Canada-based InMed Pharmaceuticals is a preclinical biotech company that specializes in developing novel drug therapies by manufacturing cannabinoids with the potential to have a therapeutic effect on specific diseases.
There's been a lot of focus lately on InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) breakthrough proprietary biosynthesis technology, and how it could unlock a $6 Billion Industry.
As the marijuana market continues its widespread growth, researchers remain merely at the threshold of exploring the manifold potential medical applications of cannabis.
Specialized holding company SinglePoint, Inc. (OTC: SING) this morning announced that it has signed a Letter of Intent (“LOI”) to acquire a Denver, Colorado-based company that is approaching $1 million in annual revenue.
InMed Pharmaceuticals (CSE: IN, OTCQB: IMLFF) a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced today an update to its investors and stakeholders on the significant advancements in its proprietary technology for the microbial biosynthesis of cannabinoids..
Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning provided an update to its investors on the significant advancements in the development of its proprietary technology for the microbial biosynthesis of cannabinoids.
Cannabis Wheaton Income Corp. (TSX VENTURE: CBW) welcomes Kanata Earth Inc. as the first participant in the recently announced Wheaton Licensing Program and the cornerstone of its First Nations strategy.
While developments in U.S. marijuana markets have no trouble attracting headlines, many seasoned investors have discovered a more predictable method of capitalizing on the cannabis boom by turning their attention to the north.
